From: Effects of abciximab on key pattern of human coronary restenosis in vitro: impact of the SI/MPL-ratio
Migration (%)
HCMSMC
C
100
0,0002 μg/ml Abciximab
136,29 ± 8,66
0,002 μg/ml Abciximab
136,68 ± 2,97
0,02 μg/ml Abciximab
132,43 ± 10,01
0,2 μg/ml Abciximab
120,37 ± 6,01
2 μg/ml Abciximab
110,81 ± 10,0
20 μg/ml Abciximab
98,17 ± 13,23